Ovid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines.

Ovid’s most advanced investigational medicine, OV101 (gaboxadol), is currently in phase 3 clinical development for the treatment of Angelman syndrome with data expected in the 4Q 2020 and in earlier clinical development for Fragile X syndrome. Ovid is also developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare developmental and epileptic encephalopathies (DEEs) and expects to initiate pivotal trials for OV935 in 2021.